#ESMOAsia25
New prospective data from #ESMOAsia25 show that in MRI-positive #ProstateCancer, TB+iSB is non-inferior to standard TB+SB, potentially streamlining diagnosis and reducing unnecessary biopsy cores.
#ESMODailyReporter 📌 https://ow.ly/5hUa50XTkno

January 9, 2026 at 10:00 AM
KANDLELIT-001:As presented at #ESMOAsia25, the next-generation KRAS G12C inhibitor MK-1084 continues to show manageable safety and encouraging antitumour activity in advanced #CRC, as monotherapy and in combination regimens.
#ESMODailyReporter 📌 https://ow.ly/hkAI50XTkiQ

January 8, 2026 at 10:35 AM
In the #ESMODailyReporter, Umberto Malapelle explains how concomitant analysis of DNA and RNA can advance cancer characterisation and guide clinical decision making, highlighting data presented at #ESMOAsia25
📌 https://ow.ly/bGI350XM8f6

#PrecisionOncology

December 19, 2025 at 10:30 AM
🌍 Uniting the Asia-Pacific oncology community: 4,550+ participants, 170+ speakers, 71 sessions, 70+ countries & 940+ abstracts.

🙌 ESMO Asia 2025 sets a new record in advancing cancer care in Asia! #ESMOAsia25 #esmomeetings

🔗 https://ow.ly/aiwM50XGitY
December 10, 2025 at 5:00 AM
🙌 To everyone who powered ESMO Asia 2025—thank you! From pioneering science to global collaboration, your contributions shaped an inspiring congress.
📅 See you next year in Singapore, 4–6 Dec 2026! #esmomeetings #ESMOAsia25

🔗 buff.ly/J1q4Zzv
December 9, 2025 at 8:32 AM
The IKCC team is fully mobilised for #ESMOAsia25 in Singapore. Dr Munisamy Murallitharan shared the results from the IKCC global patient survey on “knowledge gaps and disparities in kidney cancer across Asia”, during a session chaired by Ravindran Kanesvaran. (1/3)
December 7, 2025 at 12:36 PM
#ESMOAsia25: Studies in cancer of unknown primary (#CUP) highlight the need to perform routine comprehensive #GenomicProfiling and then provide access to the appropriate #TargetedTherapy. Find out more in the #ESMODailyReporter ➡️https://ow.ly/sK6H50XF5t7

December 7, 2025 at 11:05 AM
#ESMOAsia25: #ClinicalTrials investigated antibody–drug conjugates (#ADCs) with payloads other than topoisomerase I inhibitors and targets beyond HER2 in attempts to minimise cross-resistance. Read more in the #ESMODailyReporter ➡️https://ow.ly/Eb7l50XF5sN
Paolo Tarantino, MD
December 7, 2025 at 9:30 AM
Join us at booth B111, hall 4 at #ESMOAsia25 for our final booth talks, including sessions around Foundation Medicine’s tissue-based RNA sequencing test, our clonal hematopoiesis algorithm and use cases around AI and precision medicine. Find out more: spkl.io/63320Agvl6
December 6, 2025 at 11:00 PM
#ESMOAsia25: Impressive results from the Chinese LUMINET-1 phase III trial confirm and extend previous findings with 177Lu-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours (#GEP-NETs).
Read more in the #ESMODailyReporter ➡️https://ow.ly/mUuE50XEwSo
December 6, 2025 at 1:30 PM
Josephine Contreras-Tolentino discusses why acknowledging population diversity matters. As shown at #ESMOAsia25, ethnicity differences can impact on presentation and tolerability, which can influence treatment selection.
➡️Read more: https://ow.ly/161g50XEwRu

#ESMODailyReporter
December 6, 2025 at 10:18 AM
Our #BoothTalks series are underway at #ESMOAsia25! Learn more about Saturday’s sessions below. Click here for more information: spkl.io/63320AgmGr
December 5, 2025 at 11:00 PM
#ESMOAsia25: Encouraging phase II findings were presented with the p53 reactivator, rezatapopt, in patients with heavily pre-treated solid tumours expressing the TP53 Y220C mutation.
📌Read more: https://ow.ly/htXy50XCCKL

#ESMODailyReporter
December 5, 2025 at 3:15 PM
ESMO is excited to announce the #ESMOMeritAward recipients, selected by the Congress Scientific Committee for the exceptional scientific merit of their abstracts. #ESMOAsia25
📌 https://ow.ly/tko150XCK64
December 5, 2025 at 1:32 PM
#ESMOAsia25: The CLDN18.2-targeting antibody–drug conjugate (#ADC), JS107 in combination, achieved an impressive response rate in the first-line treatment of CLDN18.2-high #GastricCancer in a phase I #ClinicalTrial.
📌 Read more: https://ow.ly/MIw750XCBfZ

#ESMODailyReporter
December 5, 2025 at 11:05 AM
🙌Today, we witnessed the power of togetherness at #ESMOAsia25. Crowded rooms, meaningful discussions, and groundbreaking research, all united by one mission: improving patient outcomes in Asia. #esmomeetings

👉 Together, we shape the future of oncology: buff.ly/qHVAi4F
December 5, 2025 at 10:01 AM
In the #ESMODailyReporter, Eileen Yi Ling Poon discusses addressing the medical and psychosocial needs of adolescents and young adults (#AYA) w/ cancer, providing individualised treatment, targeted emotional support and age-appropriate information: https://ow.ly/O94S50XCBee

#ESMOAsia25
December 5, 2025 at 8:10 AM
📣 Welcome to ESMO Asia 2025!
Together we bring dedication, expertise and shared purpose to one of the most important oncology meetings in the Asia-Pacific region.
Let’s move forward as one. #ESMOAsia25 #esmomeetings

🔗 buff.ly/z5gybDc
December 5, 2025 at 1:02 AM